236 related articles for article (PubMed ID: 23250956)
21. BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.
Roulstone V; Pedersen M; Kyula J; Mansfield D; Khan AA; McEntee G; Wilkinson M; Karapanagiotou E; Coffey M; Marais R; Jebar A; Errington-Mais F; Melcher A; Vile R; Pandha H; McLaughlin M; Harrington KJ
Mol Ther; 2015 May; 23(5):931-942. PubMed ID: 25619724
[TBL] [Abstract][Full Text] [Related]
22. Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.
Spender LC; Ferguson GJ; Liu S; Cui C; Girotti MR; Sibbet G; Higgs EB; Shuttleworth MK; Hamilton T; Lorigan P; Weller M; Vincent DF; Sansom OJ; Frame M; Dijke PT; Marais R; Inman GJ
Oncotarget; 2016 Dec; 7(50):81995-82012. PubMed ID: 27835901
[TBL] [Abstract][Full Text] [Related]
23. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.
Phadke MS; Sini P; Smalley KS
Mol Cancer Ther; 2015 Jun; 14(6):1354-64. PubMed ID: 25873592
[TBL] [Abstract][Full Text] [Related]
24. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.
Ciuffreda L; Del Bufalo D; Desideri M; Di Sanza C; Stoppacciaro A; Ricciardi MR; Chiaretti S; Tavolaro S; Benassi B; Bellacosa A; Foà R; Tafuri A; Cognetti F; Anichini A; Zupi G; Milella M
Neoplasia; 2009 Aug; 11(8):720-31. PubMed ID: 19649202
[TBL] [Abstract][Full Text] [Related]
25. Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations.
Hartman ML; Talar B; Sztiller-Sikorska M; Nejc D; Czyz M
Oncotarget; 2016 Feb; 7(8):9026-40. PubMed ID: 26824319
[TBL] [Abstract][Full Text] [Related]
26. ATP-Citrate Lyase Epigenetically Potentiates Oxidative Phosphorylation to Promote Melanoma Growth and Adaptive Resistance to MAPK Inhibition.
Guo W; Ma J; Yang Y; Guo S; Zhang W; Zhao T; Yi X; Wang H; Wang S; Liu Y; Dai W; Chen X; Shi Q; Wang G; Gao T; Li C
Clin Cancer Res; 2020 Jun; 26(11):2725-2739. PubMed ID: 32034077
[TBL] [Abstract][Full Text] [Related]
27. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
28. The mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor PD184352 (CI-1040) selectively induces apoptosis in malignant schwannoma cell lines.
Mattingly RR; Kraniak JM; Dilworth JT; Mathieu P; Bealmear B; Nowak JE; Benjamins JA; Tainsky MA; Reiners JJ
J Pharmacol Exp Ther; 2006 Jan; 316(1):456-65. PubMed ID: 16239399
[TBL] [Abstract][Full Text] [Related]
29. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
[TBL] [Abstract][Full Text] [Related]
30. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R
Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642
[TBL] [Abstract][Full Text] [Related]
31. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of Mek 1/2 kinase activity and stimulation of melanogenesis by 5,7-dimethoxycoumarin treatment of melanoma cells.
Alesiani D; Cicconi R; Mattei M; Bei R; Canini A
Int J Oncol; 2009 Jun; 34(6):1727-35. PubMed ID: 19424591
[TBL] [Abstract][Full Text] [Related]
33. GLI2 and M-MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells.
Javelaud D; Alexaki VI; Pierrat MJ; Hoek KS; Dennler S; Van Kempen L; Bertolotto C; Ballotti R; Saule S; Delmas V; Mauviel A
Pigment Cell Melanoma Res; 2011 Oct; 24(5):932-43. PubMed ID: 21801332
[TBL] [Abstract][Full Text] [Related]
34. Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.
Beloueche-Babari M; Jamin Y; Arunan V; Walker-Samuel S; Revill M; Smith PD; Halliday J; Waterton JC; Barjat H; Workman P; Leach MO; Robinson SP
Br J Cancer; 2013 Sep; 109(6):1562-9. PubMed ID: 23942066
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells.
Ambrosini G; Khanin R; Carvajal RD; Schwartz GK
Mol Cancer Ther; 2014 Aug; 13(8):2073-80. PubMed ID: 24899684
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
Kundu A; Quirit JG; Khouri MG; Firestone GL
Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional induction of Smurf2 ubiquitin ligase by TGF-beta.
Ohashi N; Yamamoto T; Uchida C; Togawa A; Fukasawa H; Fujigaki Y; Suzuki S; Kitagawa K; Hattori T; Oda T; Hayashi H; Hishida A; Kitagawa M
FEBS Lett; 2005 May; 579(12):2557-63. PubMed ID: 15862290
[TBL] [Abstract][Full Text] [Related]
38. Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.
Ferguson J; Arozarena I; Ehrhardt M; Wellbrock C
Oncogene; 2013 Jan; 32(1):86-96. PubMed ID: 22310287
[TBL] [Abstract][Full Text] [Related]
39. Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models.
Watanabe K; Tanimura S; Uchiyama A; Sakamoto T; Kawabata T; Ozaki K; Kohno M
Clin Cancer Res; 2010 Feb; 16(4):1170-8. PubMed ID: 20145173
[TBL] [Abstract][Full Text] [Related]
40. A novel stilbene-like compound that inhibits melanoma growth by regulating melanocyte differentiation and proliferation.
Stueven NA; Schlaeger NM; Monte AP; Hwang SL; Huang CC
Toxicol Appl Pharmacol; 2017 Dec; 337():30-38. PubMed ID: 29042215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
